3-Fluoro-PCP
| 3-Fluoro-PCP | |
|---|---|
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 2201-00-9 |
| PubChem | 447196 |
| DrugBank | |
| ChemSpider | 395086 |
| KEGG | |
3-Fluoro-PCP (3'-Fluorophencyclidine) is a dissociative drug that is chemically related to phencyclidine (PCP). It is part of the arylcyclohexylamine class of compounds and is known for its hallucinogenic and anesthetic effects.
Chemical Structure and Properties[edit]
3-Fluoro-PCP has the IUPAC name 1-[1-(3-fluorophenyl)cyclohexyl]piperidine. The compound consists of a cyclohexane ring bonded to a piperidine ring and a fluorophenyl group. The presence of the fluorine atom in the phenyl ring distinguishes it from other PCP analogs.
Pharmacology[edit]
3-Fluoro-PCP acts primarily as an NMDA receptor antagonist, similar to other compounds in the arylcyclohexylamine class. This action is responsible for its dissociative and anesthetic properties. The compound may also interact with other neurotransmitter systems, contributing to its complex effects.
Effects[edit]
The effects of 3-Fluoro-PCP are similar to those of PCP and other dissociatives. Users may experience hallucinations, euphoria, dissociation, and analgesia. The intensity and duration of these effects can vary based on the dose and individual sensitivity.
Legal Status[edit]
The legal status of 3-Fluoro-PCP varies by country. In some jurisdictions, it may be classified as a controlled substance due to its potential for abuse and lack of accepted medical use.
Safety and Risks[edit]
As with other dissociative drugs, the use of 3-Fluoro-PCP carries significant risks. These include psychosis, neurotoxicity, and potential for addiction. The long-term effects of 3-Fluoro-PCP use are not well-studied, and its safety profile remains largely unknown.
See Also[edit]
References[edit]
 | This medical article is a stub. You can help WikiMD by expanding the page. |
